B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses.
Immune evasion by tumors includes several different mechanisms, including the inefficiency of antigen presenting cells (APCs) to trigger anti-tumor T cell responses. B lymphocytes may display a pro-tumoral role but can also be modulated to function as antigen presenting cells to T lymphocytes, capab...
Saved in:
| Main Authors: | , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2018-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0199034&type=printable |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850231055583281152 |
|---|---|
| author | Renata Ariza Marques Rossetti Noely Paula Cristina Lorenzi Kaori Yokochi Maria Beatriz Sartor de Faria Rosa Luciana Benevides Paulo Francisco Ramos Margarido Edmund Chada Baracat Jesus Paula Carvalho Luisa Lina Villa Ana Paula Lepique |
| author_facet | Renata Ariza Marques Rossetti Noely Paula Cristina Lorenzi Kaori Yokochi Maria Beatriz Sartor de Faria Rosa Luciana Benevides Paulo Francisco Ramos Margarido Edmund Chada Baracat Jesus Paula Carvalho Luisa Lina Villa Ana Paula Lepique |
| author_sort | Renata Ariza Marques Rossetti |
| collection | DOAJ |
| description | Immune evasion by tumors includes several different mechanisms, including the inefficiency of antigen presenting cells (APCs) to trigger anti-tumor T cell responses. B lymphocytes may display a pro-tumoral role but can also be modulated to function as antigen presenting cells to T lymphocytes, capable of triggering anti-cancer immune responses. While dendritic cells, DCs, are the best APC population to activate naive T cells, DCs or their precursors, monocytes, are frequently modulated by tumors, displaying a tolerogenic phenotype in cancer patients. In patients with cervical cancer, we observed that monocyte derived DCs are tolerogenic, inhibiting allogeneic T cell activation compared to the same population obtained from patients with precursor lesions or cervicitis. In this work, we show that B lymphocytes from cervical cancer patients respond to treatment with sCD40L and IL-4 by increasing the CD80+CD86+ population, therefore potentially increasing their ability to activate T cells. To test if B lymphocytes could actually trigger anti-tumor T cell responses, we designed an experimental model where we harvested T and B lymphocytes, or dendritic cells, from tumor bearing donors, and after APC stimulation, transplanted them, together with T cells into RAG1-/- recipients, previously injected with tumor cells. We were able to show that anti-CD40 activated B lymphocytes could trigger secondary T cell responses, dependent on MHC-II expression. Moreover, we showed that dendritic cells were resistant to the anti-CD40 treatment and unable to stimulate anti-tumor responses. In summary, our results suggest that B lymphocytes may be used as a tool for immunotherapy against cancer. |
| format | Article |
| id | doaj-art-e557f1f6327b472d94ca0f56b347e154 |
| institution | OA Journals |
| issn | 1932-6203 |
| language | English |
| publishDate | 2018-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj-art-e557f1f6327b472d94ca0f56b347e1542025-08-20T02:03:39ZengPublic Library of Science (PLoS)PLoS ONE1932-62032018-01-01137e019903410.1371/journal.pone.0199034B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses.Renata Ariza Marques RossettiNoely Paula Cristina LorenziKaori YokochiMaria Beatriz Sartor de Faria RosaLuciana BenevidesPaulo Francisco Ramos MargaridoEdmund Chada BaracatJesus Paula CarvalhoLuisa Lina VillaAna Paula LepiqueImmune evasion by tumors includes several different mechanisms, including the inefficiency of antigen presenting cells (APCs) to trigger anti-tumor T cell responses. B lymphocytes may display a pro-tumoral role but can also be modulated to function as antigen presenting cells to T lymphocytes, capable of triggering anti-cancer immune responses. While dendritic cells, DCs, are the best APC population to activate naive T cells, DCs or their precursors, monocytes, are frequently modulated by tumors, displaying a tolerogenic phenotype in cancer patients. In patients with cervical cancer, we observed that monocyte derived DCs are tolerogenic, inhibiting allogeneic T cell activation compared to the same population obtained from patients with precursor lesions or cervicitis. In this work, we show that B lymphocytes from cervical cancer patients respond to treatment with sCD40L and IL-4 by increasing the CD80+CD86+ population, therefore potentially increasing their ability to activate T cells. To test if B lymphocytes could actually trigger anti-tumor T cell responses, we designed an experimental model where we harvested T and B lymphocytes, or dendritic cells, from tumor bearing donors, and after APC stimulation, transplanted them, together with T cells into RAG1-/- recipients, previously injected with tumor cells. We were able to show that anti-CD40 activated B lymphocytes could trigger secondary T cell responses, dependent on MHC-II expression. Moreover, we showed that dendritic cells were resistant to the anti-CD40 treatment and unable to stimulate anti-tumor responses. In summary, our results suggest that B lymphocytes may be used as a tool for immunotherapy against cancer.https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0199034&type=printable |
| spellingShingle | Renata Ariza Marques Rossetti Noely Paula Cristina Lorenzi Kaori Yokochi Maria Beatriz Sartor de Faria Rosa Luciana Benevides Paulo Francisco Ramos Margarido Edmund Chada Baracat Jesus Paula Carvalho Luisa Lina Villa Ana Paula Lepique B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses. PLoS ONE |
| title | B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses. |
| title_full | B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses. |
| title_fullStr | B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses. |
| title_full_unstemmed | B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses. |
| title_short | B lymphocytes can be activated to act as antigen presenting cells to promote anti-tumor responses. |
| title_sort | b lymphocytes can be activated to act as antigen presenting cells to promote anti tumor responses |
| url | https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0199034&type=printable |
| work_keys_str_mv | AT renataarizamarquesrossetti blymphocytescanbeactivatedtoactasantigenpresentingcellstopromoteantitumorresponses AT noelypaulacristinalorenzi blymphocytescanbeactivatedtoactasantigenpresentingcellstopromoteantitumorresponses AT kaoriyokochi blymphocytescanbeactivatedtoactasantigenpresentingcellstopromoteantitumorresponses AT mariabeatrizsartordefariarosa blymphocytescanbeactivatedtoactasantigenpresentingcellstopromoteantitumorresponses AT lucianabenevides blymphocytescanbeactivatedtoactasantigenpresentingcellstopromoteantitumorresponses AT paulofranciscoramosmargarido blymphocytescanbeactivatedtoactasantigenpresentingcellstopromoteantitumorresponses AT edmundchadabaracat blymphocytescanbeactivatedtoactasantigenpresentingcellstopromoteantitumorresponses AT jesuspaulacarvalho blymphocytescanbeactivatedtoactasantigenpresentingcellstopromoteantitumorresponses AT luisalinavilla blymphocytescanbeactivatedtoactasantigenpresentingcellstopromoteantitumorresponses AT anapaulalepique blymphocytescanbeactivatedtoactasantigenpresentingcellstopromoteantitumorresponses |